Spironolactone may save the day with resistant hypertension

Kuritzky, Louis
March 2011
Internal Medicine Alert;2/28/2011 Supplement, p32
The article reports on a study conducted by M. Engbaek and colleagues which discovers the effectiveness of spironolactone (SPIR), an aldosterone antagonist with modest diuretic activity, in decreasing blood pressure independent of aldosterone status.


Related Articles

  • Aldosterone Receptor Antagonists for Hypertension: What Do They Offer? Liew, Danny; Krum, Henry // Drugs;2003, Vol. 63 Issue 19, p1963 

    Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases. Its actions, once thought to be limited to the distal convoluted tubule of the kidney, are now recognised to be wide-ranging, including interactions with...

  • Aldosterone Antagonism Fails to Attenuate Age-Associated Left Ventricular Fibrosis. Hyun Seok Hwang; Cirrincione, Georgina; Thomas, D. Paul; McCormick, Richard J.; Boluyt, Marvin O. // Journals of Gerontology Series A: Biological Sciences & Medical ;Apr2007, Vol. 62 Issue 4, p382 

    Collagen accumulates disproportionately in cardiac remodeling induced by hypertension and associated with advancing age. Spironolactone (Spiro), an aldosterone antagonist, attenuates the accumulation of collagen induced by hypertension. It was hypothesized that Spiro would attenuate the...

  • The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy. Sica, Domenic A. // Current Drug Safety;Jan2007, Vol. 2 Issue 1, p71 

    Spironolacotone and eplerenone are mineralocorticoid-blocking agents. These compounds block both the epithelial and non-epithelial actions of aldosterone with the latter assuming increasing clinical importance. Spironolactone and eplerenone both effectively reduce blood pressure either as mono-...

  • Aldosterone Antagonists � Last Man Standing? Armstrong, Paul W. // New England Journal of Medicine;1/6/2011, Vol. 364 Issue 1, p79 

    The author reflects on aldosterone antagonists in the treatment of heart failure. It says that in the turn of the millennium, there are four cardiac medicines developed before 1960 that survived namely aspirin, digoxin, warfarin and spironolactone. It highlights two studies whose findings have...

  • Hyperkalaemia in the age of aldosterone antagonism. Chapagain, A.; Ashman, N. // QJM: An International Journal of Medicine;Nov2012, Vol. 105 Issue 11, p1049 

    Hyperkalaemia is well recognized as a medical emergency. However, with the publication of trials showing benefit with renin-aldosterone axis suppression in heart failure, the epidemiology of patients presenting with hyperkalaemia has changed. The reported incidence of rate of serious...

  • Aldactide 50.  // Royal Society of Medicine: Medicines;2002, p42 

    The article presents information on Aldactide 50, a proprietary, prescription-only compound preparation of the aldosterone-antagonist and potassium-sparing spironolactone and the thiazide-type diuretic hydroflumethiazide. This drug can be used for heart failure treatment and is available as tablets.

  • Spironolactone.  // Reactions Weekly;3/10/2007, Issue 1142, p21 

    The article presents a case report of a man with congestive heart failure and was receiving spironolactone daily. It states that a condition called gynecomastia which is an increasing breast size in the patient during his treatment made his medication replaced by eplerenone. The author mentions...

  • EXPERIENCE WITH THE USE OF AN ALDOSTERONE ANTAGONIST IN SELECTED HYPERTENSIVE PATIENTS. Kert, Morley J.; Tarr, Lester W.; Frank, Stanley; Gold, Ernest; Okun, Ronald; Maxwell, Morton // Angiology;Nov1972, Vol. 23 Issue 10, p617 

    Eleven patients selected from a hypertension clinic were given spironolactone (300 mg/day) for four weeks. Six of the patients had spontaneous hypokalemia prior to the spironolactone therapy and five were control patients. Spironolactone caused significant reduction in blood pressure...

  • Aldosterone Antagonists: The Most Underutilized Class of Heart Failure Medications. Guglin, Maya; Awad, Khaled Esmaeel; Polavaram, Latha; Vankayala, Hema // American Journal of Cardiovascular Drugs;2007, Vol. 7 Issue 1, p75 

    BACKGROUND: Aldosterone antagonists have been proven to be beneficial in severe heart failure (HF) as a result of systolic dysfunction. We sought to determine if there is a disparity in their utilization compared with ACE inhibitors and β-adrenoceptor antagonists (β-blockers). METHODS:...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics